OOO. B. Orlenko

O. B. Orlenko

*This is an algorithmically generated author record based on publicly available information.

O. B. Orlenko has a total of 1 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experimental assessment of the addiction liability of N-(y-aminobutyryl)-1-aza-4,7,10,13-tetraoxacyclopentadecane hydrochloride (C-3) in rats

    by N. I. Voloshchuk, O. B. Orlenko

    The safe clinical use of centrally acting analgesics remains limited by the risk of tolerance, physical dependence, and addictive behavior associated with prolonged administration. Therefore, preclinical evaluation of abuse liability represents an essential component of pharmacological screening for novel analgesic compounds. The aim of this study was to experimentally assess the addictive potential of compound C-3 (N-(γ-aminobutyryl)-1-aza-4,7,10,13-tetraoxacyclopentadecane hydrochloride) by investigating reward-related behavior, tolerance development, cross-tolerance, and withdrawal manifestations in rats. The study was conducted in adult male Wistar rats (n = 7 per group). Reward properties were evaluated using the conditioned place preference (CPP) paradigm. Antinociceptive effect and tolerance were assessed in the tail-flick test following 28-day intraperitoneal administration of C-3 (1 mg/kg), while cross-tolerance was examined after morphine administration (5 mg/kg). Statistical analysis was performed using nonparametric tests (Mann–Whitney U test, Wilcoxon signed-rank test, Friedman test; p<0.05). C-3 produced a significant antinociceptive effect, increasing latency by 58.9% compared with baseline values (p0.05). Discontinuation of chronic treatment did not induce hyperalgesia or clinically relevant signs of spontaneous withdrawal. Moreover, morphine responsiveness remained preserved after prolonged C-3 exposure, demonstrating absence of cross-tolerance and suggesting lack of long-term μ-opioid receptor desensitization. Collectively, these findings indicate a favorable addiction-related profile of C-3 under the studied dosing regimen. Further investigations should explore broader dose ranges and clarify receptor-mediated mechanisms underlying its pharmacological effects.